| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Bedtime Administration of Amlodipine Versus Lisinopril
| Condition: |
Hypertension |
| Intervention: |
Drug: Amlodipine |
| Outcome Measures: |
Change in mean sleep-time systolic blood pressure after addition of a bedtime dose of amlodipine versus Lisinopril; Changes in mean sleep-time diastolic, awake systolic and diastolic blood pressures, including comparison of % achieving target BP; Impact of individual medications on sleep-time blood pressure drop (dipping status); Association of baseline renin levels to sleep-time blood pressure drop; Association of baseline renin levels with response to amlodipine versus Lisinopril; Association of baseline dipping status with response to amlodipine versus Lisinopril; Association of age and response to amlodipine versus Lisinopril |
|
| 2 |
Recruiting
|
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
| Conditions: |
Breast Cancer; Cardiac Toxicity |
| Interventions: |
Drug: Coreg CR®; Drug: Lisinopril; Other: placebo |
| Outcome Measures: |
Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of LVEF; Comparison of the LVEF of each treatment group with the placebo arm; Number of trastuzumab courses completed without interruption; Quality-of-life changes as assessed by EORTC-QLQ-C30 questionnaire at baseline and at the end of treatment; Long-term effects of study drugs as assessed at 18 and 24 months (or 6 and 12 months after completion of trastuzumab therapy) |
|
| 3 |
Recruiting
|
Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
| Conditions: |
Dyspnea; Non-small Cell Lung Cancer; Small Cell Lung Cancer |
| Interventions: |
Drug: Lisinopril; Drug: placebo |
| Outcome Measures: |
Incidence of grade 3 or higher hypotension, acute kidney injury, allergic reaction, or anaphylaxis, as measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Incidence of adverse events as measured using the NCI CTCAE version 4.0; Quality of life, assessed using lung cancer symptom scale (LCSS), Functional Assessment of Cancer Treatment Lung Cancer (FACT-L), and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer (EORTC-QLQ-LC13); Incidence of acute respiratory distress (dyspnea), measured using the maximum score, at any time, of the shortness of breath question on the LCSS; Patient-level symptoms as measured using the Symptom Experience Questionnaire (SEQ) |
|
| 4 |
Not yet recruiting
|
CAndesartan vs Lisinopril Effects on the BRain
| Conditions: |
Hypertension; Mild Cognitive Impairment |
| Interventions: |
Drug: Candesartan; Drug: Lisinopril |
| Outcome Measures: |
Executive function (EXAMINER score); Perfusion and Vasoreactivity (VR); rs-fMRI |
|
| 5 |
Recruiting
|
Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
| Conditions: |
Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy |
| Intervention: |
Drug: Coenzyme Q10 and Lisinopril |
| Outcome Measure: |
myocardial performance index (MPI) |
|
| 6 |
Unknown †
|
Paramedic Initiated Lisinopril For Acute Stroke Treatment
| Condition: |
Stroke |
| Interventions: |
Drug: Lisinopril; Drug: Placebo |
| Outcome Measures: |
Number of participants enrolled per month; Proportion fulfilling eligibility criteria; Proportion attended by research trained paramedic; Proportion enrolled by research trained paramedic; Proportion approached but not enrolled; Additional time spent on scene; Paramedic compliance; Hospital staff compliance; Proportion completing study medication; Clinical outcome measures; Adverse events |
|
| 7 |
Recruiting
|
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
| Condition: |
Type 2 Diabetes |
| Interventions: |
Drug: ACEI or ARB; Drug: Lisinopril |
| Outcome Measures: |
Change in renal blood flow (RBF); Change in Proteinuria |
|
| 8 |
Recruiting
|
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
| Condition: |
Hypertension |
| Intervention: |
Drug: Lisinopril, Atenolol |
| Outcome Measure: |
One type of blood pressure medication will better treat individuals with certain genetic backgrounds. |
|
| 9 |
Recruiting
|
Non-invasive Haemodynamic Assessment in Hypertension
| Condition: |
Arterial Hypertension |
| Interventions: |
Drug: Lisinopril; Drug: Telmisartan; Drug: Nebivolol; Drug: Indapamide/hydrochlorothiazide; Drug: Amlodipine |
| Outcome Measures: |
24-h mean Systolic Blood Pressure (in ABPM); 24-h mean Diastolic Blood Pressure (in ABPM); daytime mean Systolic Blood Pressure (in ABPM); daytime mean Diastolic Blood Pressure (in ABPM); night-time mean Systolic Blood Pressure (in ABPM); night-time mean Diastolic Blood Pressure (in ABPM); Systolic Blood Pressure (in OBPM); Diastolic Blood Pressure (in OBPM); change from baseline in Systolic Blood Pressure (in OBPM) at 3 months; change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months; change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months; change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months; change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months; change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months; change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months; change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months |
|
| 10 |
Recruiting
|
The VALDIATE-D Study
| Conditions: |
Type 2 Diabetes; Obesity |
| Interventions: |
Drug: Calcitriol and Lisinopril; Drug: Placebo |
| Outcome Measures: |
Circulating RAS activity after calcitriol/placebo therapy; Renal-vascular tissue RAS activity after calcitriol/placebo therapy; Renal-vascular RAS activity and urien protein after calcitriol/Lisinopril therapy; Adiponectin levels; Adipose-tissue RAS measures |
|
| 11 |
Not yet recruiting
|
Single Pill to Avert Cardiovascular Events
| Condition: |
Cardiovascular Disease |
| Interventions: |
Drug: polipillV1; Drug: polipillV2; Drug: usual care |
| Outcome Measures: |
compliance with treatment; changed in blood pressure; changes in LDL-cholesterol levels; the main reason for non compliance with treatment; safety of poli pill measures by laboratorial tests; combined outcome |
|
| 12 |
Recruiting
|
ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
| Condition: |
HIV |
| Interventions: |
Drug: Lisinopril; Drug: Placebo |
| Outcome Measures: |
Change in HIV RNA (copies/mil CD4); Change in HIV DNA (copies/mil CD4) |
|
| 13 |
Recruiting
|
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
| Condition: |
Hyperparathyroidism |
| Interventions: |
Drug: captopril; Drug: Lisinopril |
| Outcome Measures: |
Parathyroid hormone, before and after, ACE inhibitor administration; Serum and urinary aldosterone measurements before and after ACE inhibitor use; Serum calcium before and after ACE inhibitor administration |
|
| 14 |
Recruiting
|
Risk Factor Control Before Orthopedic Surgery
| Conditions: |
Osteoarthritis; Cardiovascular Disease |
| Interventions: |
Drug: Metoprolol; Drug: Lisinopril; Drug: Atorvastatin; Behavioral: Lifestyle counseling |
| Outcome Measures: |
Composite of cardiovascular events; Modified composite of cardiovascular events |
|
| 15 |
Not yet recruiting
|
Microvascular Disease Exercise Trial
| Condition: |
Coronary Microvascular Disease |
| Interventions: |
Behavioral: Exercise Program; Drug: Medical Therapy |
| Outcome Measures: |
Change in MPR on CMR imaging from baseline with intensive medical therapy + supervised exercise versus intensive medical therapy alone.; Incremental change in MPR with exercise over intensive medical therapy alone in the exercise subgroup; Identification of reduced MPR (<2.0 ml/g/min) and borderline reduced MPR |
|
| 16 |
Not yet recruiting
|
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
| Condition: |
Hypertension |
| Interventions: |
Drug: Take ACE-I; Drug: Hold ACE-I |
| Outcome Measures: |
Intraoperative Hypotension; Acute Renal Failure; Low blood pressure subgroup; Older age subgroup; Postoperative Hypertension |
|
| 17 |
Recruiting
|
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
| Conditions: |
Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease |
| Interventions: |
Drug: Any antihypertensive medication alone or in combination; Device: Ambulatory blood pressure monitoring |
| Outcome Measures: |
To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.; To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.; To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.; To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.; To evaluate, for all previous objectives, potential differences between men and women.; To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment. |
|
| 18 |
Unknown †
|
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
| Conditions: |
Cardiovascular Disease; Chronic Kidney Disease |
| Interventions: |
Drug: angiotensin converting enzyme inhibitor; Drug: Lisinopril |
| Outcome Measure: |
There may be a statistical correlation between eGFR(estimated glomerular function) and PWV (pulse wave velocity) in patients with CKD, the addition of an ACE inhibitor will decrease PWV in all groups, but to a greater extent in patients wil CKD. |
|
| 19 |
Recruiting
|
Renal Denervation in Patients After Acute Coronary Syndrome
| Conditions: |
Acute Coronary Syndrome; Arterial Hypertension |
| Interventions: |
Procedure: Renal denervation; Drug: Metoprolol; Drug: Lisinopril |
| Outcome Measures: |
cardiovascular death; myocardium infarction; stroke; repeat revascularization; blood pressure changes; CCS and NYHA; heart rhythm disturbances; intima-media index; IVS thickness; restenosis; diastolic disfunction |
|
| 20 |
Unknown †
|
Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?
| Condition: |
Heart Failure |
| Intervention: |
Drug: - Angiotensin conversing enzyme inhibitors: enalapril, captopril, Lisinopril, ramipril, trandolapril. |
| Outcome Measures: |
Change from baseline in quality of life; Mortality; Rehospitalisation; Cardiovascular events; Cardiac fibrosis; Quality of life |
|
